Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapi...

Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes. Building on a 2.6 billion dollar framework, this new phase adds equity investment to scale microfluidic biomanufacturing. This represents a systemic shift for the AM industry, moving from mechanical implants to functional biological cures for the 11 percent of the population with diabetes. 🧬🏥 #3DPrinting #Bioprinting #Diabetes #Pharma #Innovation